Dennis R. Hill M.D. Medical Director of the HDR Prostate Brachytherapy Center: Prostate Cancer Genetic Test Not Ready for Prime Time
PR Web |
Dr. Hill says that there is considerable interest in genetic testing in prostate cancer because there has been success in breast cancer. Genetic breast cancer tests can be predictive of a patient's response to breast cancer therapy but there is not an equivalent advantage with prostate cancer. “You are either at higher risk or lower risk. There are no firm cutoffs that would steer decisions toward a different treatment in prostate cancer,” he said. “If we have a new biomarker, we need to be able to demonstrate the ability to affect clinical management or treatment decisions." However, Dr. Hill pointed out that, for the majority of patients that have had the test in his practice it did not change the risk category that was predicted by the standard parameters of PSA, gleason score, clinical stage, biopsy cores positive and perineural invasion.
Dr. Hill says that the test, which is expensive at about
*2013 Annual Meeting of the
About
Dr. Hill is a board certified radiation oncologist doing High Dose Rate brachytherapy exclusively since 2004 and has published scholarly articles on the subject. His office is located at:
Read the full story at http://www.prweb.com/releases/2013/11/prweb11291335.htm
Copyright: | (c) 2013 PRWEB.COM Newswire |
Wordcount: | 477 |
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News